NCT05324462 (SPIRIT) is a clinical trial of IDegLira in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT05324462?

NCT05324462 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT05324462?

Interventions in NCT05324462: IDegLira.

What condition does NCT05324462 study?

NCT05324462 studies Diabetes Mellitus, Type 2.

Is NCT05324462 still recruiting?

NCT05324462 is currently completed. Last updated 9 November 2022.

Last reviewed 2022-11-09 · How we verify

NCT05324462: SPIRIT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia

Completed Last updated 9 November 2022

What this trial tests

trial testing IDegLira in Diabetes Mellitus, Type 2 in 175 participants. Completed in 15 July 2022.

Timeline

22 March 2022

Primary endpoint
15 July 2022

15 July 2022

Quick facts

Lead sponsor	Novo Nordisk A/S
Status	Completed
Study type	OBSERVATIONAL
Enrollment	175
Start date	22 March 2022
Primary completion	15 July 2022
Estimated completion	15 July 2022
Sites	6 locations across Colombia

Drugs / interventions tested

IDegLira — full drug profile →

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the glycaemic control and other clinical parameters in adult patients previously treated with basal insulin (with or without OADs) and switched to IDegLira in real-world clinical practice in Colombia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

SPIRIT: Assessing Clinical Parameters Associated with Using IDegLira in Patients with Type 2 Diabetes in a Real-World Setting in Colombia.
Ramírez-Rincón A, Henao-Carrillo D, Omeara M, Oliveros J, et al · · 2024 · cited 2× · PMID 38717577 · DOI 10.1007/s13300-024-01593-8
SPIRIT – Assessing clinical parameters associated with using IDegLira in patients with Type 2 Diabetes in a real-world setting in Colombia: a single arm, retrospective, chart review study
Ramírez A, Carrillo DH, Omeara M, Oliveros J, et al · · 2023 · DOI 10.21203/rs.3.rs-3059502/v1

Verify or expand the search:

Other trials of IDegLira

Trials testing the same drug.

NCT06113341 — A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Livi · withdrawn
NCT06408532 — The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes · Phase 4 · not yet recruiting
NCT05545800 — Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy · Phase 3 · unknown
NCT05479591 — A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin an · withdrawn
NCT04838743 — GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in · completed

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05324462 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 9 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05324462.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing